Pharma BD Deal Intelligence
Bristol Myers Squibb's acquisition strategy continued with the Turning Point Therapeutics buyout, part of a broader push to strengthen its precision oncology…
FDA granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients 12+ with NTRK gene fusion-positive solid tumors on June 13, 2024.
EMA EPAR: Augtyro (repotrectinib) granted EU conditional marketing authorisation on 13 January 2025 for ROS1+ advanced NSCLC and NTRK+ solid tumors.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Bristol-Myers Squibb acquired Turning Point Therapeutics for approximately $4.1 billion ($76.00 per share) in an all-cash tender offer, gaining repotrectinib (Augtyro), a next-generation ROS1/NTRK inhibitor with differentiated activity in ROS1-positive non-small cell lung cancer.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Turning Point Therapeutics Inc. (this deal) | 2022 | $4.1B | 70 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2022 deals · Bristol-Myers Squibb Company deals · Oncology deals